You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Cediranib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Cediranib?

Cediranib is an investigational drug.

There have been 102 clinical trials for Cediranib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2006.

The most common disease conditions in clinical trials are Carcinoma, Ovarian Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), AstraZeneca, and NRG Oncology.

Recent Clinical Trials for Cediranib
TitleSponsorPhase
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsNRG OncologyPhase 2
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsNational Cancer Institute (NCI)Phase 2
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerNational Cancer Institute (NCI)Phase 2

See all Cediranib clinical trials

Clinical Trial Summary for Cediranib

Top disease conditions for Cediranib
trials02468101214161820CarcinomaOvarian NeoplasmsLung NeoplasmsCarcinoma, Ovarian Epithelial[disabled in preview]
Top clinical trial sponsors for Cediranib
trials0510152025303540455055National Cancer Institute (NCI)AstraZenecaNRG Oncology[disabled in preview]

See all Cediranib clinical trials

Development Update and Market Projection for the Drug Candidate: Cediranib

Introduction to Cediranib

Cediranib, also known as AZD2171 or Recentin, is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. It targets all three VEGFR tyrosine kinases (VEGFR-1, -2, and -3), which are crucial for the formation of new blood vessels that support tumor growth. This mechanism makes cediranib a promising candidate for the treatment of various cancers.

Current Clinical Trials and Development Status

Ovarian Cancer

Cediranib has been evaluated in several clinical trials for the treatment of ovarian cancer. The Phase III GY004 trial, sponsored by the US National Cancer Institute (NCI) and led by NRG Oncology, investigated the efficacy and safety of cediranib in combination with olaparib (Lynparza) versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer. However, this trial did not meet its primary endpoint of statistically significant improvement in progression-free survival (PFS)[1].

Despite this setback, cediranib is still being explored in other trials for ovarian cancer, including the Phase II CONCERTO trial and the Phase II/III GY005 trial, also sponsored by the NCI[1].

Other Cancers

Cediranib is under clinical development for a wide range of cancers, including:

  • Small-Cell Lung Cancer: Currently in Phase II, with a 26% phase transition success rate (PTSR) benchmark for progressing into Phase III[4].
  • Triple-Negative Breast Cancer: Part of the Phase II trial studying cediranib in combination with olaparib for advanced solid tumors[3].
  • Pancreatic Ductal Adenocarcinoma (PDAC): Also included in the Phase II trial for advanced solid tumors[3].
  • Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC): Being evaluated in the same Phase II trial[3].

Safety and Tolerability

The safety and tolerability profiles of cediranib have generally been consistent with those known for VEGFR inhibitors. The combination of cediranib with olaparib has shown manageable side effects, although the trials have highlighted the need for careful monitoring and management of potential toxicities[1][3].

Mechanism of Action and Advantages

Anti-Angiogenic Effects

Cediranib works by inhibiting the VEGFR tyrosine kinases, thereby blocking the formation of new blood vessels that tumors need to grow. This anti-angiogenic effect can be particularly beneficial when combined with other therapies, such as PARP inhibitors like olaparib[1][5].

Synergy with Chemotherapy

Studies suggest that cediranib may offer advantages over other anti-angiogenic agents like bevacizumab, particularly in terms of synergy with chemotherapy. Cediranib's ability to abrogate cell cycle progression and enhance the efficacy of chemotherapy makes it a promising candidate for combination therapies[5].

Market Projection

Global Solid Tumors Market

The global solid tumors market is expected to grow significantly, valued at USD 209.61 billion in 2021 and projected to reach USD 901.27 billion by 2029, with a CAGR of 20.0% during the forecast period. This growth is driven by increasing incidence rates of various cancers and the development of new therapies, including targeted therapies like cediranib[2].

Potential Market Impact

If cediranib successfully navigates its current clinical trials and gains regulatory approval, it could significantly impact the market for solid tumors. Given its broad spectrum of activity across multiple cancer types, cediranib could become a key player in the oncology market, particularly in combination with other therapies like PARP inhibitors and chemotherapies.

Challenges and Future Directions

Regulatory Hurdles

Despite its potential, cediranib faces regulatory hurdles, as evidenced by the failure to meet primary endpoints in some trials. The drug's development will depend on the outcomes of ongoing and future trials, as well as the ability to demonstrate significant clinical benefits over existing treatments[1].

Competitive Landscape

The oncology market is highly competitive, with numerous drugs and combinations under development. Cediranib will need to demonstrate clear advantages over existing therapies to secure a strong market position. Collaboration between AstraZeneca and MSD, as well as other partners, will be crucial in advancing cediranib through the clinical development pipeline[1].

Key Takeaways

  • Clinical Trials: Cediranib is currently in various clinical trials for multiple cancer types, including ovarian cancer, small-cell lung cancer, and pancreatic ductal adenocarcinoma.
  • Mechanism of Action: It inhibits VEGFR tyrosine kinases, blocking tumor angiogenesis.
  • Market Potential: The global solid tumors market is growing rapidly, and successful approval of cediranib could position it as a significant player.
  • Challenges: Regulatory hurdles and a competitive market landscape must be navigated for cediranib to achieve market success.

FAQs

What is cediranib and how does it work?

Cediranib is an oral VEGFR inhibitor that blocks the formation of new blood vessels supporting tumor growth by targeting VEGFR-1, -2, and -3 tyrosine kinases.

Which cancers is cediranib being evaluated for?

Cediranib is being evaluated for various cancers, including ovarian cancer, small-cell lung cancer, triple-negative breast cancer, pancreatic ductal adenocarcinoma, and non-small cell lung cancer.

What was the outcome of the Phase III GY004 trial for cediranib in ovarian cancer?

The Phase III GY004 trial did not meet its primary endpoint of statistically significant improvement in progression-free survival (PFS) when cediranib was added to olaparib compared to platinum-based chemotherapy.

How does cediranib compare to other anti-angiogenic agents like bevacizumab?

Cediranib may offer advantages over bevacizumab due to its ability to abrogate cell cycle progression and enhance the efficacy of chemotherapy, although this needs further clinical validation.

What is the projected market growth for the global solid tumors market?

The global solid tumors market is projected to grow from USD 209.61 billion in 2021 to USD 901.27 billion by 2029, with a CAGR of 20.0%.

Sources

  1. AstraZeneca Press Release: "Update on Phase III GY004 trial for cediranib added to Lynparza in platinum-sensitive relapsed ovarian cancer."
  2. Data Bridge Market Research: "Global Solid Tumors Market – Industry Trends and Forecast to 2029."
  3. ClinicalTrials.gov: "Cediranib in Combination With Olaparib in Advanced Solid Tumors."
  4. Pharmaceutical Technology: "Cediranib maleate by AstraZeneca for Small-Cell Lung Cancer."
  5. MDPI Pharmaceuticals: "Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy."

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.